Zepp Health Corporation
NYSE:ZEPPConsumer Electronics
-$0.03 today
- Market cap
- $50.84M
- Beta
- 1.78
- P/E (TTM)
- -0.1
- EPS (TTM)
- -$282.07
Volume 0.04M
Average 0.13M
ZEPP Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Zepp Health CorporationNYSE: ZEPP
Stock-Based Compensation · Q4 FY2025 · quarter ended Dec 2025
Stock-based compensation grows in line with its trailing trend
Q4 FY2025 stock-based compensation of CN¥17.43M rose 151.0% year over year, in line with the +151.0% change in trailing-twelve-month stock-based compensation. Over 3 fiscal years it compounded at +33.8% a year.
Context
- Stock-based compensation amounted to 1.0% of revenue in FY2025, up 0.6 pp from a year earlier.
- Stock-based compensation increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +151.0% holds above the trailing-twelve-month pace of +151.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
CNY · from the cash flow
- Latest · FY2025
- 17.43M CNY
- Year-over-year change
- +264.7%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 17.43M | +264.7% |
| FY2024 | 2024-12-31 | 4.78M | -45.7% |
| FY2023 | 2023-12-31 | 8.79M | +20.9% |
| FY2022 | 2022-12-31 | 7.27M | — |
| FY2021 | 2021-12-31 | 0 | — |
Stock-Based Compensation vs competitors
How ZEPP compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +151.0% is the 2nd highest of 7, against a peer median of -2.5%.
- Stock-based compensation amounts to 0.9% of revenue for ZEPP, versus a peer median of 5.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $24.57M USD | -27.8% | -20.2% | 17.5% | |
| LTM Dec 2025 | CN¥17.43M CNY | +151.0% | +33.8% | 0.9% | |
| LTM Mar 2026 | $13.02M USD | -19.3% | -8.5% | 0.6% | |
| LTM Mar 2026 | $12.47M USD | +219.0% | — | 1.9% | |
SVCOSilvaco Group, Inc. Common Stock | LTM Mar 2026 | $8.42M USD | +14.3% | — | 12.6% |
| LTM Mar 2026 | $7.95M USD | -44.9% | -29.1% | 5.2% | |
| LTM Mar 2026 | $6.34M USD | +82.1% | +16.0% | 34.2% | |
| FY2025 | $0 USD | — | — | 0.0% | |
| Peer median (excluding ZEPP) | — | -2.5% | -14.4% | 5.2% | |
Competitors are the stored peer set for ZEPP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 136.02M | (43.35M) | (31.09M) | (75.81M) | (280.18M) |
| Depreciation & Amortization | 51.21M | 8.71M | 7.69M | 5.02M | 31.71M |
| Deferred Income Tax | (18.45M) | (9.92M) | (2.88M) | 13.45M | 15.65M |
| Stock-Based Compensation | 0 | 7.27M | 8.79M | 4.78M | 17.43M |
| Change in Working Capital | (620.52M) | (82.26M) | 47.88M | 7.66M | (109.97M) |
| Accounts Receivables | 300.79M | 3.13M | 43.8M | 404K | (80.68M) |
| Inventory | (82.05M) | 27.92M | 51.91M | 5.56M | (154.48M) |
| Accounts Payables | (664.51M) | (135.34M) | (27.82M) | 14.81M | 197.86M |
| Other Working Capital | (174.76M) | 22.03M | (20.02M) | (13.11M) | (72.67M) |
| Other Non-Cash Items | 119.98M | 2.44M | 12.21M | 20.51M | 145.71M |
| Operating Cash Flow | (331.77M) | (117.11M) | 42.6M | (24.39M) | (179.65M) |
| Capital Expenditures | (45.46M) | (1.47M) | (1.68M) | (1.49M) | (5.48M) |
| Acquisitions (Net) | 35.99M | 60K | 427K | 0 | 0 |
| Purchases of Investments | (1.06B) | (4.32M) | (282K) | (7M) | 0 |
| Sales of Investments | 24.68M | 1.8M | 5.93M | 5.16M | 11.67M |
| Other Investing Activities | 0 | (2.57M) | 3.25M | 1.66M | 2.29M |
| Investing Cash Flow | (1.06B) | (6.24M) | 7.73M | (1.58M) | 10.35M |
| Debt Repayment | 654.58M | 16.55M | (46.98M) | (1.65M) | (51.29M) |
| Common Stock Issued | 5.39M | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | (13.58M) | (8.16M) | (2.52M) | (2.28M) | (8.66M) |
| Dividends Paid | 0 | (6.31M) | 0 | 0 | 0 |
| Other Financing Activities | 0 | 40.28M | 7.82M | 4.4M | 233.61M |
| Financing Cash Flow | 646.39M | 42.37M | (41.68M) | 477K | 173.66M |
| Effect of Forex Changes | 33.47M | (14.77M) | (9.31M) | (4.24M) | 11.01M |
| Net Change in Cash | (707.46M) | (95.76M) | (652K) | (29.73M) | 15.37M |
| Free Cash Flow | (377.22M) | (118.59M) | 40.92M | (25.88M) | (185.14M) |
Zepp Health Corporation
NYSE:ZEPP
Intrinsic Alpha fair value
Locked
Current Price
$3.55
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.